Wanyong Chen
Overview
Explore the profile of Wanyong Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu C, Zhou C, Xia W, Zhou Y, Qiu Y, Weng J, et al.
Nat Commun
. 2024 Feb;
15(1):1009.
PMID: 38307859
Tumor-secreted factors contribute to the development of a microenvironment that facilitates the escape of cancer cells from immunotherapy. In this study, we conduct a retrospective comparison of the proteins secreted...
2.
Zhou Q, Yin Y, Yu M, Gao D, Sun J, Yang Z, et al.
Redox Biol
. 2022 Sep;
56:102458.
PMID: 36116159
Guanosine triphosphate binding protein 4 (GTPBP4) is a key regulator of cell cycle progression and MAPK activation. However, how its biological properties intersect with cellular metabolism in hepatocellular carcinoma (HCC)...
3.
Atyah M, Zhou C, Zhou Q, Chen W, Weng J, Wang P, et al.
Int J Gen Med
. 2022 Jan;
15:737-748.
PMID: 35082522
Background: Nuclear factor (erythroid-derived 2)-like 2 (NRF2) functions decline with age; however, cancer cells can hijack its pathways to ensure survival and aggressiveness. Yet, the role of NRF2 in hepatocellular...
4.
Zhou Q, Zhou C, Yin Y, Chen W, Liu C, Atyah M, et al.
Ann Transl Med
. 2021 Apr;
9(5):402.
PMID: 33842623
Background: Microvascular invasion (MVI) is a significant hazard factor that influences the recurrence and survival of hepatocellular carcinoma (HCC) patients after undergoing hepatectomy. This study aimed to develop and validate...
5.
Weng J, Zhou C, Zhou Q, Chen W, Yin Y, Atyah M, et al.
J Hepatocell Carcinoma
. 2021 Apr;
8:193-209.
PMID: 33824863
Background: Hepatocellular carcinoma (HCC) is a malignant tumor with great variation in prognosis among individuals. Changes in metabolism influence disease progression and clinical outcomes. The objective of this study was...
6.
Sun J, Zhou C, Zhao Y, Zhang X, Chen W, Zhou Q, et al.
Redox Biol
. 2021 Mar;
41:101942.
PMID: 33770521
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as...
7.
Zhou C, Weng J, Liu C, Zhou Q, Chen W, Hsu J, et al.
Am J Cancer Res
. 2020 Oct;
10(9):2768-2784.
PMID: 33042616
Despite the use of immune checkpoint blockade (ICB) therapy for hepatocellular carcinoma (HCC), developing more effective immunotherapy and predicting HCC's response to ICB therapy remain top priorities. Ribosomal protein S3A...
8.
High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection
Zhou C, Sun J, Zheng Z, Weng J, Atyah M, Zhou Q, et al.
Ann Transl Med
. 2020 May;
8(7):466.
PMID: 32395510
Background: Ribosomal protein S11 (RPS11), a member of ribosomal protein family, is reported to overexpress in diverse malignancies and correlates with tumor recurrence. However, our current knowledge on RPS11 in...
9.
Zhou C, Liu C, Liu W, Chen W, Yin Y, Li C, et al.
Theranostics
. 2020 Apr;
10(10):4627-4643.
PMID: 32292519
Hepatocellular carcinoma (HCC) remains one of the most refractory malignancies worldwide. Schlafen family member 11 (SLFN11) has been reported to play an important role in inhibiting the production of human...
10.
A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
Zhou C, Wang S, Zhou Q, Zhao J, Xia X, Chen W, et al.
Front Oncol
. 2019 Nov;
9:1160.
PMID: 31781487
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive solid malignant tumors worldwide. Increasing investigations demonstrate that long non-coding RNAs (lncRNAs) expression is abnormally dysregulated in cancers. It is...